STOCK TITAN

Bio-Techne Corporation - $TECH STOCK NEWS

Welcome to our dedicated page for Bio-Techne Corporation news (Ticker: $TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne Corporation stock.

Bio-Techne Corporation (NASDAQ: TECH) is a pioneering global life sciences company based in Minnesota. Specializing in bioactive tools and reagents, Bio-Techne serves the research and clinical diagnostic communities. The company's extensive product portfolio, exceeding 275,000 items, supports scientific investigations into biological processes and disease mechanisms, facilitating both drug discovery and accurate clinical testing.

Bio-Techne operates through two main segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment, which accounts for 75% of revenue, provides reagents such as antibodies and analytical instruments for life sciences research. The Diagnostics and Genomics segment, representing 25% of revenue, offers diagnostic reagents and molecular diagnostics, with a strong footprint in spatial biology products.

Geographically, the United States is Bio-Techne's largest market, contributing about 55% of its revenue. The company also maintains significant operations in Europe, the Middle East, Africa (20%), the UK (5%), and Asia-Pacific (15%).

In recent news, Bio-Techne has been active on multiple fronts:

  • Legal Actions: Bio-Techne initiated legal proceedings in the Unified Patent Court to address patent infringements related to its RNAscope® ISH technology by Molecular Instruments, Inc.
  • Innovations: Partnering with Novomol-Dx, Bio-Techne introduced the Bio-Marker Pathfinder (BMP), a point-of-care ocular biomarker kit leveraging its Ella™ platform for rapid diagnostics in ophthalmic diseases.
  • Strategic Collaborations: Bio-Techne entered a distribution agreement with Thermo Fisher Scientific to expand product access across Europe and announced continued collaboration with Regulus Therapeutics, highlighting positive results in ADPKD treatment using Bio-Techne's Simple Western™ platforms.
  • Financial Performance: Bio-Techne reported a modest 3% revenue increase for Q3 FY2024 despite challenging market conditions, underscoring strong operational execution and strategic investments.
  • Product Showcases: The company unveiled its MauriceFlex™ System at the 72nd ASMS Conference, demonstrating innovative solutions for protein characterization.

With over 3,100 employees worldwide, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023. The company continues to drive significant advancements in life sciences and healthcare through its robust portfolio and strategic initiatives.

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will present at several upcoming investor conferences. These include the William Blair 44th Annual Growth Conference on June 4, 2024, the Jefferies Global Healthcare Conference on June 6, 2024, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. Each presentation will be accessible via a live webcast on Bio-Techne's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
conferences
-
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) will showcase its MauriceFlex™ System at the 72nd ASMS Conference on Mass Spectrometry from June 2-6, 2024, in Anaheim, California.

The MauriceFlex System offers advanced imaged capillary isoelectric focusing (icIEF) solutions, including fractionation, and supports various mass spectrometric methods for protein characterization.

Highlights include a breakfast seminar on June 4th featuring Dr. Chris Heger and Dr. Sara Carillo discussing the system's applications, particularly in protein charge heterogeneity and cell and gene therapy.

Bio-Techne will also present seven posters detailing collaborations with industry leaders like Pfizer and 908 Devices, showcasing advancements in charge isoform characterization.

Will Geist, President of Protein Sciences, emphasized the system's unique capabilities and collaborative efforts at ASMS to advance life-saving therapies.

Visit Bio-Techne at Booth #161 and learn more at bio-techne.com/mauriceflex.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
none
-
Rhea-AI Summary

ScaleReady, in cooperation with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has unveiled a $20 million G-Rex® Grant Program aimed at advancing cell and gene therapy (CGT) development. The initiative offers up to $300,000 in G-Rex® devices, reagents, equipment, and support services to qualifying academic and commercial institutions. The program intends to reduce barriers to CGT innovation, enabling faster and more cost-effective development. Industry leaders emphasize the program's potential to enhance research timelines, streamline transitions to GMP manufacturing, and improve data quality for IND applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will present at the 2024 Leerink Partners Healthcare Crossroads Conference.

The presentation is scheduled for May 29, 2024, at 8:40 a.m. CDT. Interested parties can access a live webcast of the presentation on Bio-Techne's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences
-
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) and Regulus Therapeutics Inc. announced positive top-line results from the second cohort of their Phase 1b MAD study of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The collaboration, ongoing since 2020, utilizes Bio-Techne's Simple Western™ platforms and ExosomeDx CLIA laboratory for biomarker analysis. Regulus developed assays to measure polycystin 1 and 2 levels, key biomarkers in ADPKD, using Bio-Techne’s technology. This milestone highlights the clinical potential of RGLS8429 and advances the study, aiming to improve global healthcare with innovative therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary

Molecular Instruments announced a significant legal victory with the Patents Court of the High Court of England and Wales ruling in their favor against Advanced Cell Diagnostics, a Bio-Techne group company (NASDAQ: TECH). The court revoked two European patents (UK) held by Advanced Cell Diagnostics and dismissed their infringement claims against Molecular Instruments regarding the HCR™ RNA-ISH technology. This action resulted in Advanced Cell Diagnostics being ordered to pay £1.35 million (approximately $1.72 million) to Molecular Instruments. The judgment by Mr. Justice Meade, delivered on April 23, 2024, concluded that the patents were invalid due to obviousness based on overwhelming primary evidence. Dr. Harry Choi, CEO of Molecular Instruments, expressed satisfaction with the outcome, emphasizing their commitment to supporting UK researchers with advanced molecular tools.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has confirmed that Kim Kelderman, President and CEO, will present at the BofA Securities Health Care Conference on May 14, 2024. The presentation will be available via live webcast on the company's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences
-
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) will present at the 27th Annual Meeting of the American Society of Gene & Cell Therapy, showcasing its cell and gene therapy workflow solutions. The event will feature speaker sessions, poster presentations, and a multimedia experience highlighting Bio-Techne's innovative tools and solutions for advancing cell and gene therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences
-
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) reported third-quarter fiscal 2024 results with organic revenue up 2%, GAAP EPS at $0.31, adjusted EPS at $0.48, and strong commercial execution in Diagnostics & Genomics segment. Cash flow increased by 31% to $223.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.22%
Tags
News
Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) declared a quarterly dividend of $0.08 per share for the quarter ended March 31, 2024. The dividend will be payable on May 24, 2024, to common shareholders of record on May 13, 2024. The company is a global life sciences provider of tools and bioactive reagents for research and clinical diagnostics, generating $1.1 billion in net sales in fiscal 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.22%
Tags
dividends

FAQ

What does Bio-Techne Corporation do?

Bio-Techne Corporation provides innovative bioactive tools and reagents that support scientific investigations, drug discovery, and clinical diagnostics.

What are Bio-Techne's main business segments?

Bio-Techne operates through two main segments: Protein Sciences and Diagnostics and Genomics.

Where is Bio-Techne headquartered?

Bio-Techne is headquartered in Minnesota, USA.

Which markets does Bio-Techne serve?

Bio-Techne serves the pharma, biotech, academic, and diagnostic markets globally, with significant operations in the USA, Europe, Asia-Pacific, and other regions.

What recent legal actions has Bio-Techne taken?

Bio-Techne has taken legal action against Molecular Instruments, Inc. in the Unified Patent Court to address patent infringements related to its RNAscope® ISH technology.

What is the Bio-Marker Pathfinder (BMP) kit?

Co-developed with Novomol-Dx, the BMP kit is an ocular biomarker kit running on Bio-Techne's Ella™ platform, designed for rapid diagnostics in ophthalmic diseases.

What was Bio-Techne's financial performance in Q3 FY2024?

Bio-Techne reported a 3% revenue increase for Q3 FY2024, highlighting strong operational execution despite challenging market conditions.

What is the MauriceFlex™ System?

The MauriceFlex™ System is an imaged capillary isoelectric focusing (icIEF) solution for protein characterization, recently showcased at the ASMS Conference.

How many employees does Bio-Techne have?

Bio-Techne has approximately 3,100 employees worldwide.

What was Bio-Techne's revenue in fiscal 2023?

Bio-Techne generated over $1.1 billion in net sales in fiscal 2023.

Bio-Techne Corporation

Nasdaq:TECH

TECH Rankings

TECH Stock Data

12.20B
155.39M
0.97%
100.54%
3.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
MINNEAPOLIS

About TECH

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.